[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640579":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":57,"collaborators":11,"id":61,"slug":11,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Rawalpindi Institute of Cardiology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group Dexmed","ACTIVE_COMPARATOR",null,[13],"Drug: IV dexmedetomidine",{"label":15,"type":10,"description":11,"interventionNames":16},"Group Lignocaine",[17],"Drug: IV Lignocaine",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","IV dexmedetomidine","0.5 Mcg\u002Fkg of Dexmedetomidine will be given 10 minutes before laryngoscopy",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"IV Lignocaine","Patients will be given 1.5 mg\u002Fkg of Lignocaine 3 minutes before laryngoscopy",[15],[29],{"name":30,"affiliation":5,"role":31},"Qudsia Anjum, MBBS,FCPS","STUDY_CHAIR",[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Namrah Zujaj, MBBS","CONTACT","+92 305 2636980","zujajnamrah20@gmail.com",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Rawalpindi","Punjab Province","46000","Pakistan","PK",{"type":47,"coordinates":48},"Point",[49,50],73.0479,33.59733,{"lat":50,"lon":49},[53],{"name":54,"role":35,"phone":55,"phoneExt":11,"email":56},"Asma Shabbir, MBBS,FCPS","+92 333 5161142","Research@ricrwp.edu.pk",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Namrah Zujaj","Principal Investigator","100640579",false,"NCT07611890","Dexmedetomidine vs Lignocaine for Reducing Intubation-Induced Hemodynamic Responses in Cardiac Surgery: A Randomized Controlled Trial","Comparison of Intravenous Dexmedetomidine and Lignocaine in Reducing Hemodynamic Responses During Laryngoscopy and Endotracheal Intubation In Patients Undergoing Cardiac Surgery at Rawalpindi Institute Of Cardiology- A Randomized Controlled Trial","Inclusion Criteria:\n\nAmerican Society of Anesthesiologists (ASA) physical status III-IV. Patients who are at risk of cardiovascular events\n\nExclusion Criteria:\n\n1. Patients with known hypersensitivity to dexmedetomidine and Lignocaine.\n2. Patients on medications that could interfere with the study (e.g., beta-blockers, calcium channel blockers).\n3. Pregnant or lactating women.\n4. Patients with a history of airway anomalies or difficult intubation.","ALL","18 Years","65 Years",{"count":71,"type":72},70,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","After confirming eligibility, written informed consent will be obtained by a trained team member who is not involved in assigning treatment or giving the study medication. Each participant will receive a unique study number to protect privacy. Participants will be randomly assigned to receive one of the study medications using a chance-based method.The study medication will be administered through a vein before placement of the breathing tube. Blood pressure and pulse rate will be measured before the procedure and at several time points after the breathing tube is inserted.",[78,79,80],"Laryngoscopic Stress Response","Dexmedetomidine","Lignocaine",[82,79,80,83],"Laryngoscopic stress response","Cardiac surgery","2026-05-21",{"date":86,"type":87},"2026-05-28","ACTUAL",{"date":84,"type":87},{"date":90,"type":72},"2026-08-21",{"name":5,"class":6},1]